KR100463263B1 - 골길이 성장 촉진 효과를 가지는 가시오가피 추출물 및 이를 함유하는 약학적 제제 - Google Patents
골길이 성장 촉진 효과를 가지는 가시오가피 추출물 및 이를 함유하는 약학적 제제 Download PDFInfo
- Publication number
- KR100463263B1 KR100463263B1 KR10-2001-0062208A KR20010062208A KR100463263B1 KR 100463263 B1 KR100463263 B1 KR 100463263B1 KR 20010062208 A KR20010062208 A KR 20010062208A KR 100463263 B1 KR100463263 B1 KR 100463263B1
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- growth
- bone length
- layer
- length growth
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000000284 extract Substances 0.000 title claims abstract description 72
- 241001632410 Eleutherococcus senticosus Species 0.000 title claims abstract description 6
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 4
- 230000001737 promoting effect Effects 0.000 title abstract description 11
- 230000008468 bone growth Effects 0.000 title description 12
- 210000000988 bone and bone Anatomy 0.000 claims abstract description 59
- 230000012010 growth Effects 0.000 claims abstract description 53
- 208000037824 growth disorder Diseases 0.000 claims abstract description 14
- 239000000825 pharmaceutical preparation Substances 0.000 claims abstract description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 57
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 33
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 32
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 26
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 25
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 9
- 239000004480 active ingredient Substances 0.000 claims description 8
- 230000002265 prevention Effects 0.000 claims description 7
- 241000208340 Araliaceae Species 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 239000012046 mixed solvent Substances 0.000 claims description 3
- 206010013883 Dwarfism Diseases 0.000 claims description 2
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 2
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 2
- 239000012141 concentrate Substances 0.000 claims description 2
- 235000008434 ginseng Nutrition 0.000 claims description 2
- 230000036435 stunted growth Effects 0.000 claims 1
- 240000001439 Opuntia Species 0.000 abstract description 30
- 235000013389 Opuntia humifusa var. humifusa Nutrition 0.000 abstract description 30
- 231100000252 nontoxic Toxicity 0.000 abstract description 2
- 230000003000 nontoxic effect Effects 0.000 abstract description 2
- 239000004098 Tetracycline Substances 0.000 description 24
- 229960002180 tetracycline Drugs 0.000 description 24
- 229930101283 tetracycline Natural products 0.000 description 24
- 235000019364 tetracycline Nutrition 0.000 description 24
- 150000003522 tetracyclines Chemical class 0.000 description 24
- 230000000694 effects Effects 0.000 description 21
- 230000001965 increasing effect Effects 0.000 description 18
- 238000000034 method Methods 0.000 description 16
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 15
- 102000013275 Somatomedins Human genes 0.000 description 15
- 241000700159 Rattus Species 0.000 description 13
- 238000002360 preparation method Methods 0.000 description 13
- 108010049931 Bone Morphogenetic Protein 2 Proteins 0.000 description 10
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 description 10
- 210000004349 growth plate Anatomy 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 9
- 206010020880 Hypertrophy Diseases 0.000 description 8
- 210000001612 chondrocyte Anatomy 0.000 description 8
- 239000002953 phosphate buffered saline Substances 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 7
- 239000000122 growth hormone Substances 0.000 description 7
- 239000002504 physiological saline solution Substances 0.000 description 7
- 102000018997 Growth Hormone Human genes 0.000 description 6
- 108010051696 Growth Hormone Proteins 0.000 description 6
- 150000001720 carbohydrates Chemical class 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 230000011164 ossification Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000005520 cutting process Methods 0.000 description 4
- 230000001969 hypertrophic effect Effects 0.000 description 4
- 238000007912 intraperitoneal administration Methods 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 230000000284 resting effect Effects 0.000 description 4
- 238000012453 sprague-dawley rat model Methods 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 108090000445 Parathyroid hormone Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 239000012223 aqueous fraction Substances 0.000 description 3
- 239000002034 butanolic fraction Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 210000000845 cartilage Anatomy 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 238000007710 freezing Methods 0.000 description 3
- 230000008014 freezing Effects 0.000 description 3
- 235000020710 ginseng extract Nutrition 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 230000000984 immunochemical effect Effects 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 210000002414 leg Anatomy 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 230000002062 proliferating effect Effects 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 210000002303 tibia Anatomy 0.000 description 3
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 2
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 101000993347 Gallus gallus Ciliary neurotrophic factor Proteins 0.000 description 2
- 102000002265 Human Growth Hormone Human genes 0.000 description 2
- 108010000521 Human Growth Hormone Proteins 0.000 description 2
- 239000000854 Human Growth Hormone Substances 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 2
- 102100037611 Lysophospholipase Human genes 0.000 description 2
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 102000003982 Parathyroid hormone Human genes 0.000 description 2
- 108010058864 Phospholipases A2 Proteins 0.000 description 2
- 201000002154 Pterygium Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000002180 anti-stress Effects 0.000 description 2
- 230000004596 appetite loss Effects 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 235000014121 butter Nutrition 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 150000001746 carotenes Chemical class 0.000 description 2
- 235000005473 carotenes Nutrition 0.000 description 2
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 2
- 229940074393 chlorogenic acid Drugs 0.000 description 2
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 2
- 235000001368 chlorogenic acid Nutrition 0.000 description 2
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000003163 gonadal steroid hormone Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 235000021266 loss of appetite Nutrition 0.000 description 2
- 208000019017 loss of appetite Diseases 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 229960001319 parathyroid hormone Drugs 0.000 description 2
- 239000000199 parathyroid hormone Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- QJVXKWHHAMZTBY-GCPOEHJPSA-N syringin Chemical compound COC1=CC(\C=C\CO)=CC(OC)=C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 QJVXKWHHAMZTBY-GCPOEHJPSA-N 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- HGXBRUKMWQGOIE-AFHBHXEDSA-N (+)-pinoresinol Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@@H]3[C@@H]([C@H](OC3)C=3C=C(OC)C(O)=CC=3)CO2)=C1 HGXBRUKMWQGOIE-AFHBHXEDSA-N 0.000 description 1
- PEYUIKBAABKQKQ-AFHBHXEDSA-N (+)-sesamin Chemical compound C1=C2OCOC2=CC([C@H]2OC[C@H]3[C@@H]2CO[C@@H]3C2=CC=C3OCOC3=C2)=C1 PEYUIKBAABKQKQ-AFHBHXEDSA-N 0.000 description 1
- TVHDZSRRHQKNEZ-UHFFFAOYSA-N (-) acanthoic acid Natural products OC(=O)C1(C)CCCC2(C)C3=CCC(C=C)(C)CC3CCC21 TVHDZSRRHQKNEZ-UHFFFAOYSA-N 0.000 description 1
- TVHDZSRRHQKNEZ-MGFONVBGSA-N (1r,4ar,7s,8as,10as)-7-ethenyl-1,4a,7-trimethyl-3,4,6,8,8a,9,10,10a-octahydro-2h-phenanthrene-1-carboxylic acid Chemical compound OC(=O)[C@]1(C)CCC[C@@]2(C)C3=CC[C@@](C=C)(C)C[C@@H]3CC[C@@H]21 TVHDZSRRHQKNEZ-MGFONVBGSA-N 0.000 description 1
- HSTOKWSFWGCZMH-UHFFFAOYSA-N 3,3'-diaminobenzidine Chemical compound C1=C(N)C(N)=CC=C1C1=CC=C(N)C(N)=C1 HSTOKWSFWGCZMH-UHFFFAOYSA-N 0.000 description 1
- 208000035657 Abasia Diseases 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 206010000599 Acromegaly Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229930192694 Caryophyllenol Natural products 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 244000085362 Eucalyptus consideniana Species 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 206010021925 Inferiority complex Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 208000023178 Musculoskeletal disease Diseases 0.000 description 1
- 241000906034 Orthops Species 0.000 description 1
- 102100036893 Parathyroid hormone Human genes 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000982698 Prorodonopsis coli Species 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 240000009241 Smilax aspera Species 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- ZHAFUINZIZIXFC-UHFFFAOYSA-N [9-(dimethylamino)-10-methylbenzo[a]phenoxazin-5-ylidene]azanium;chloride Chemical compound [Cl-].O1C2=CC(=[NH2+])C3=CC=CC=C3C2=NC2=C1C=C(N(C)C)C(C)=C2 ZHAFUINZIZIXFC-UHFFFAOYSA-N 0.000 description 1
- KIPLYOUQVMMOHB-MXWBXKMOSA-L [Ca++].CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(=C([O-])[C@]2(O)C(=O)C(C(N)=O)=C1O)C(=O)c1c(O)cccc1[C@@]3(C)O.CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(=C([O-])[C@]2(O)C(=O)C(C(N)=O)=C1O)C(=O)c1c(O)cccc1[C@@]3(C)O Chemical compound [Ca++].CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(=C([O-])[C@]2(O)C(=O)C(C(N)=O)=C1O)C(=O)c1c(O)cccc1[C@@]3(C)O.CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(=C([O-])[C@]2(O)C(=O)C(C(N)=O)=C1O)C(=O)c1c(O)cccc1[C@@]3(C)O KIPLYOUQVMMOHB-MXWBXKMOSA-L 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000002429 anti-coagulating effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 229940076810 beta sitosterol Drugs 0.000 description 1
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 1
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000004097 bone metabolism Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000003321 cartilage cell Anatomy 0.000 description 1
- 230000008414 cartilage metabolism Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- PEYUIKBAABKQKQ-UHFFFAOYSA-N epiasarinin Natural products C1=C2OCOC2=CC(C2OCC3C2COC3C2=CC=C3OCOC3=C2)=C1 PEYUIKBAABKQKQ-UHFFFAOYSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000002038 ethyl acetate fraction Substances 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 150000008195 galaktosides Chemical class 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 210000004195 gingiva Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 208000003906 hydrocephalus Diseases 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 230000002989 hypothyroidism Effects 0.000 description 1
- 208000003532 hypothyroidism Diseases 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229940041476 lactose 100 mg Drugs 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 210000005240 left ventricle Anatomy 0.000 description 1
- 210000001930 leg bone Anatomy 0.000 description 1
- ZOLPMMWNCLHKPX-UHFFFAOYSA-N ligustrin Natural products CC1=CCC2C1C3OC(=C)C(=O)C3C(O)CC2=C ZOLPMMWNCLHKPX-UHFFFAOYSA-N 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 229920002113 octoxynol Polymers 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 210000000287 oocyte Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229940124595 oriental medicine Drugs 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- LCCNCVORNKJIRZ-UHFFFAOYSA-N parathion Chemical compound CCOP(=S)(OCC)OC1=CC=C([N+]([O-])=O)C=C1 LCCNCVORNKJIRZ-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- OHOPKHNWLCMLSW-UHFFFAOYSA-N pinoresinol Natural products C1=C(O)C(OC)=CC(C2C3C(C(OC3)C=3C=C(CO)C(O)=CC=3)CO2)=C1 OHOPKHNWLCMLSW-UHFFFAOYSA-N 0.000 description 1
- 235000007221 pinoresinol Nutrition 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000004648 relaxation of smooth muscle Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- VRMHCMWQHAXTOR-CMOCDZPBSA-N sesamin Natural products C1=C2OCOC2=CC([C@@H]2OC[C@@]3(C)[C@H](C=4C=C5OCOC5=CC=4)OC[C@]32C)=C1 VRMHCMWQHAXTOR-CMOCDZPBSA-N 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 238000007447 staining method Methods 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- KOWMJRJXZMEZLD-UHFFFAOYSA-N syringaresinol Chemical compound COC1=C(O)C(OC)=CC(C2C3C(C(OC3)C=3C=C(OC)C(O)=C(OC)C=3)CO2)=C1 KOWMJRJXZMEZLD-UHFFFAOYSA-N 0.000 description 1
- LVUPFEOCDSHRBL-UHFFFAOYSA-N syringaresinol Natural products COc1cccc(OC)c1C2OCC3C2COC3c4c(OC)cccc4OC LVUPFEOCDSHRBL-UHFFFAOYSA-N 0.000 description 1
- QJVXKWHHAMZTBY-KSXIZUIISA-N syringin Natural products COc1cc(C=CCO)cc(OC)c1O[C@H]2O[C@@H](CO)[C@H](O)[C@@H](O)[C@@H]2O QJVXKWHHAMZTBY-KSXIZUIISA-N 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940063650 terramycin Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- BURBOJZOZGMMQF-UHFFFAOYSA-N xanthoxylol Natural products C1=C(O)C(OC)=CC=C1C1C(COC2C=3C=C4OCOC4=CC=3)C2CO1 BURBOJZOZGMMQF-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/254—Acanthopanax or Eleutherococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Medical Informatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
휴지부 | 증식부 | 성숙부 | 비대부 | |
정상군 | 24.3±7.4 | 118.4±9.7 | 72.4±7.7 | 170.8±10.5 |
가시오가피 투여군 | 25.0±11.4 | 132.7±12.1 | 71.2±8.2 | 218.5±12.5 |
Claims (5)
- 가시오가피(Acanthopanax senticosus)를 물, 저급 알코올, 헥산, 에틸 아세테이트 또는 이들의 혼합 용매로 추출, 농축 및 동결건조하여 제조한 가시오가피 추출물을 유효성분으로 함유하는 골길이 성장 장애 치료 및 예방을 위한 약학적 제제.
- 제1항에 있어서, 상기 저급 알코올은 메탄올, 에탄올 및 부탄올로 이루어진 군으로부터 선택되는 것을 특징으로 하는 약학적 제제.
- 제1항 또는 제2항에 따른 가시오가피 추출물을 n-헥산층, 에틸아세테이트층, 부탄올층 또는 물층으로 분리한 후 이를 감압농축 및 동결 건조하여 제조한 가시오가피 분획 추출물을 유효성분으로 함유하는 골길이 성장 장애 치료 및 예방을 위한 약학적 제제.
- 제1항 또는 제2항에 따른 가시오가피 추출물을 부탄올 층과 물층으로 각각 분리한 후 이를 물에 녹여 합한 다음 감압 농축하여 100% 에탄올을 첨가하여 분리된 에탄올 비가용성 분획과 가용성 분획을 감압 농축 및 동결 건조하여 제조한 가시오가피 분획 추출물을 유효성분으로 함유하는 골길이 성장 장애 치료 및 예방을 위한 약학적 제제.
- 제1항 내지 제5항 중 어느 한 항에 있어서, 상기 골길이 성장 장애는 소인증, 왜소증 및 키 성장 저하로 이루어진 군으로부터 선택되는 것을 특징으로 하는 약학적 제제.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2001-0062208A KR100463263B1 (ko) | 2001-10-09 | 2001-10-09 | 골길이 성장 촉진 효과를 가지는 가시오가피 추출물 및 이를 함유하는 약학적 제제 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2001-0062208A KR100463263B1 (ko) | 2001-10-09 | 2001-10-09 | 골길이 성장 촉진 효과를 가지는 가시오가피 추출물 및 이를 함유하는 약학적 제제 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20030030336A KR20030030336A (ko) | 2003-04-18 |
KR100463263B1 true KR100463263B1 (ko) | 2004-12-23 |
Family
ID=29563916
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR10-2001-0062208A Expired - Lifetime KR100463263B1 (ko) | 2001-10-09 | 2001-10-09 | 골길이 성장 촉진 효과를 가지는 가시오가피 추출물 및 이를 함유하는 약학적 제제 |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100463263B1 (ko) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015147538A1 (ko) * | 2014-03-26 | 2015-10-01 | 경희대학교 산학협력단 | L-아르기닌 및 오가피 추출물을 유효성분으로 포함하는 골길이 성장 촉진용 조성물 |
KR20160063717A (ko) | 2014-11-27 | 2016-06-07 | 경북대학교 산학협력단 | 가시오가피 추출물의 제조방법 및 이로부터 제조된 가시오가피 추출물을 함유하는 기능성 식품 조성물 |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20040033983A (ko) * | 2002-10-16 | 2004-04-28 | 학교법인 상지학원 | 항염증 및 항침해수용 활성을 갖는 리리오덴드린을 함유한가시오가피 수피의 추출물 및 이를 함유하는 조성물 |
KR100847343B1 (ko) * | 2006-12-08 | 2008-07-21 | 경희대학교 산학협력단 | 생약복합재 추출물을 함유하는 골길이 성장 촉진용 조성물 |
KR101972639B1 (ko) | 2016-08-22 | 2019-08-16 | 경희대학교 산학협력단 | L-아르기닌 및 오가피 추출물을 유효성분으로 포함하는 골길이 성장 촉진용 식품 조성물 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20000038805A (ko) * | 1998-12-09 | 2000-07-05 | 성재갑 | 성장호르몬 분비 촉진제 조성물 |
KR20010000470A (ko) * | 2000-10-02 | 2001-01-05 | 유근형 | 오가피 추출액 가공방법 |
KR101229668B1 (ko) * | 2010-11-10 | 2013-02-04 | 한국과학기술원 | 작업 차량의 위험 영역 표시 장치 |
KR101234439B1 (ko) * | 2003-09-25 | 2013-02-18 | 몬산토 테크놀로지 엘엘씨 | 단백질 내로의 비―표준 아미노산의 도입 방지 |
KR101275393B1 (ko) * | 2011-07-06 | 2013-06-17 | (주)에이티케이 | 사출 성형기에 적합한 히터 제어장치 |
-
2001
- 2001-10-09 KR KR10-2001-0062208A patent/KR100463263B1/ko not_active Expired - Lifetime
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20000038805A (ko) * | 1998-12-09 | 2000-07-05 | 성재갑 | 성장호르몬 분비 촉진제 조성물 |
KR20010000470A (ko) * | 2000-10-02 | 2001-01-05 | 유근형 | 오가피 추출액 가공방법 |
KR101234439B1 (ko) * | 2003-09-25 | 2013-02-18 | 몬산토 테크놀로지 엘엘씨 | 단백질 내로의 비―표준 아미노산의 도입 방지 |
KR101229668B1 (ko) * | 2010-11-10 | 2013-02-04 | 한국과학기술원 | 작업 차량의 위험 영역 표시 장치 |
KR101275393B1 (ko) * | 2011-07-06 | 2013-06-17 | (주)에이티케이 | 사출 성형기에 적합한 히터 제어장치 |
Non-Patent Citations (3)
Title |
---|
103쪽1~10줄, 104쪽실험재료, 생약학회지32권2호2001.06 * |
가시오가피(7~8, 약제학회지8권1호,1978,03) * |
도해 향약(생약)대사전’, p. 432-5 정보섭, 신민교 저, 영림사,( 1990. 01. 10) * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015147538A1 (ko) * | 2014-03-26 | 2015-10-01 | 경희대학교 산학협력단 | L-아르기닌 및 오가피 추출물을 유효성분으로 포함하는 골길이 성장 촉진용 조성물 |
KR20160063717A (ko) | 2014-11-27 | 2016-06-07 | 경북대학교 산학협력단 | 가시오가피 추출물의 제조방법 및 이로부터 제조된 가시오가피 추출물을 함유하는 기능성 식품 조성물 |
Also Published As
Publication number | Publication date |
---|---|
KR20030030336A (ko) | 2003-04-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2703004B1 (en) | Composition for improving male sexual function containing ginseng berry extract | |
JP5689117B2 (ja) | 心不全を防止及び治療するための組成物及び方法 | |
US20240415920A1 (en) | Peptide having activity of preventing hair loss or promoting hair growth, and use thereof | |
US10279003B2 (en) | Methods and compositions to reduce fat gain, promote weight loss in animals | |
CN111840508A (zh) | 一种预防及治疗男性性功能障碍的外用制剂及其应用 | |
CN108186877A (zh) | 用于气虚血瘀证心肌梗死二级预防的中药组合物 | |
US20060198913A1 (en) | Method of improvement of blood circulation | |
KR100463263B1 (ko) | 골길이 성장 촉진 효과를 가지는 가시오가피 추출물 및 이를 함유하는 약학적 제제 | |
JP2018502119A (ja) | 男性更年期症状の予防または改善用組成物 | |
US20140248380A1 (en) | Method for treating vascular inflammation, improving skin beauty and improving male sexual function using ginseng berry | |
BRPI0106382B1 (pt) | Process for obtaining decocts from vitis labrusca and vitis vinifera casts, process for obtaining the hydro-alcoholic extract, process for obtaining the hydro-alcoholic extract-ethyl acetate and pharmaceutical compositions | |
KR100404455B1 (ko) | 성장촉진추출물 및 이를 함유하는 약학적 제제 | |
KR100597563B1 (ko) | 골성장촉진활성을 갖는 엘루테로사이드 e 를 함유하는 건강기능식품 | |
Huang et al. | Benefits of Chinese medicine among patients with diabetic foot: an expert review from clinical studies | |
CN101574498B (zh) | 治疗骨质疏松症的复方鹿茸健骨胶囊及定性测定其质量的方法 | |
KR100597564B1 (ko) | 골성장 촉진활성을 갖는 엘루테로사이드 e를 함유하는약학조성물 | |
RU2238755C1 (ru) | Лечебно-профилактическое средство, обладающее гепатопротекторным, холестерино- и сахарорегулирующим действием (варианты) | |
EP3560488A1 (en) | Compositions for treating female sexual dysfunction | |
CN109395008A (zh) | 治疗骨质疏松症的中药组合物及其应用 | |
KR20200101080A (ko) | 체외충격파 치료법의 남성 성기능 개선효과 또는 남성 불임 치료효과 증진용 약학 조성물 | |
RU2805492C1 (ru) | Способ коррекции постпрандиальной гликемии | |
RU2805492C9 (ru) | Способ коррекции постпрандиальной гликемии | |
Yoon et al. | The effects of new herbal formula (KBMSI-2) on penile erection and expression of nitric oxide synthase isoforms in streptozotocin-induced diabetic rat model | |
KR20130141420A (ko) | 인삼 열매 추출물을 함유하는 혈행촉진, 혈관신생촉진, 및 허혈성 심질환 치료용 조성물 | |
KR20040011748A (ko) | 성장촉진활성을 갖는 구척 근경 추출물을 함유하는 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20011009 |
|
PA0201 | Request for examination | ||
PG1501 | Laying open of application | ||
E902 | Notification of reason for refusal | ||
PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20040211 Patent event code: PE09021S01D |
|
E701 | Decision to grant or registration of patent right | ||
PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20040913 |
|
N231 | Notification of change of applicant | ||
PN2301 | Change of applicant |
Patent event date: 20041111 Comment text: Notification of Change of Applicant Patent event code: PN23011R01D |
|
GRNT | Written decision to grant | ||
PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20041214 Patent event code: PR07011E01D |
|
PR1002 | Payment of registration fee |
Payment date: 20041215 End annual number: 3 Start annual number: 1 |
|
PG1601 | Publication of registration | ||
PR1001 | Payment of annual fee |
Payment date: 20071114 Start annual number: 4 End annual number: 4 |
|
PR1001 | Payment of annual fee |
Payment date: 20081125 Start annual number: 5 End annual number: 5 |
|
PR1001 | Payment of annual fee |
Payment date: 20091111 Start annual number: 6 End annual number: 6 |
|
PR1001 | Payment of annual fee |
Payment date: 20101210 Start annual number: 7 End annual number: 7 |
|
PR1001 | Payment of annual fee |
Payment date: 20111214 Start annual number: 8 End annual number: 8 |
|
FPAY | Annual fee payment |
Payment date: 20121016 Year of fee payment: 9 |
|
PR1001 | Payment of annual fee |
Payment date: 20121016 Start annual number: 9 End annual number: 9 |
|
FPAY | Annual fee payment |
Payment date: 20131024 Year of fee payment: 10 |
|
PR1001 | Payment of annual fee |
Payment date: 20131024 Start annual number: 10 End annual number: 10 |
|
FPAY | Annual fee payment |
Payment date: 20140911 Year of fee payment: 11 |
|
PR1001 | Payment of annual fee |
Payment date: 20140911 Start annual number: 11 End annual number: 11 |
|
FPAY | Annual fee payment |
Payment date: 20151221 Year of fee payment: 12 |
|
PR1001 | Payment of annual fee |
Payment date: 20151221 Start annual number: 12 End annual number: 12 |
|
FPAY | Annual fee payment |
Payment date: 20170214 Year of fee payment: 13 |
|
PR1001 | Payment of annual fee |
Payment date: 20170214 Start annual number: 13 End annual number: 13 |
|
FPAY | Annual fee payment |
Payment date: 20171103 Year of fee payment: 14 |
|
PR1001 | Payment of annual fee |
Payment date: 20171103 Start annual number: 14 End annual number: 14 |
|
FPAY | Annual fee payment |
Payment date: 20191001 Year of fee payment: 16 |
|
PR1001 | Payment of annual fee |
Payment date: 20191001 Start annual number: 16 End annual number: 16 |
|
PR1001 | Payment of annual fee |
Payment date: 20201005 Start annual number: 17 End annual number: 17 |
|
PC1801 | Expiration of term |
Termination date: 20220409 Termination category: Expiration of duration |